KNAW

Back to search results
Prof.dr. W. Jiskoot Person

Prof.dr. W. Jiskoot

Pagina-navigatie:
filter results
Type
Date
Accessibility
Institution

1-10 out of 31 results by:date

Save search results

  • Quality of Original and Biosimilar Epoetin Products (2011)

    Authors:Brinks, V.; Hawe, A.; Basmeleh, A.H.H.; Joachin-Rodriguez, L.; Haselberg, R.; Somsen, G.W.; Jiskoot, W.; Schellekens, H.
    In:Pharmaceutical Research, 28, 386 - 393. ISSN 0724-8741.

    Abstract:

    Purpose: To compare the quality of therapeutic erythropoietin (EPO) products, including two biosimilars, with respect to content, aggregation, isoform profile and potency. Methods: Two original products, Eprex (epoetin alfa) and Dynepo (epoetin delta), and two biosimilar products, Binocrit (epoetin

  • PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity (2011)Open access

    Authors:Keijzer, C.; Slutter, B.; Zee, R. van der; Jiskoot, W.; Eden, W. van; Broere, F.
    In:PLoS ONE [E], 6, e26684-1 - e26684-10. ISSN 1932-6203.

    Abstract:

    Development of vaccines in autoimmune diseases has received wide attention over the last decade. However, many vaccines showed limited clinical efficacy. To enhance vaccine efficacy in infectious diseases, biocompatible and biodegradable polymeric nanoparticles have gained interest as antigen delive

  • Chitosan-based delivery systems for protein therapeutics and antigens (2010)

    Authors:Amidi, M.; Mastrobattista, E.; Jiskoot, W.; Hennink, W.E.
    In:Advanced Drug Delivery Reviews, 62, 59 - 82. ISSN 0169-409x.

    Abstract:

    Therapeutic peptides/proteins and protein-based antigens are chemically and structurally labile compounds, which are almost exclusively administered by parenteral injections. Recently, non-invasive mucosal routes have attracted interest for administration of these biotherapeutics. Chitosan-based del

  • Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta (2010)

    Authors:Beers, M.M.C. van; Sauerborn, M.S.; Gilli, F.; Hermeling, S.; Brinks, V.; Schellekens, H.; Jiskoot, W.
    In:Journal of Immunological Methods, 352, 32 - 37. ISSN 0022-1759.

    Abstract:

    To date, the therapeutic efficacy of recombinant human proteins is limited by their potential to break B cell tolerance in patients. The formation of neutralising antibodies (NABs) directed against recombinant human interferon beta (rhIFNβ) is associated with a decrease in the therapeutic effect of

  • Immunological mechanism underlying the immune response to recombinant human protein therapeutics (2010)

    Authors:Sauerborn, M.S.; Brinks, V.; Jiskoot, W.; Schellekens, H.
    In:Trends in Pharmacological Sciences, 31, 53 - 59. ISSN 0165-6147.

    Abstract:

    Recombinant human (rhu) protein therapeutics are powerful tools to treat several severe diseases such as multiple sclerosis and diabetes mellitus, among others. A major drawback of these proteins is the production of anti-drug antibodies (ADAs). In some cases, these ADAs have neutralizing capacity a

  • Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: Nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. (2010)

    Authors:Slütter, B.; Bal, S.; Keijzer, C.; Mallants, R.; Hagenaars, N.; Que, I.; Kaijzel, E.; Eden, W. van; Augustijns, P.; Lowik, C.; Bouwstra, J.; Broere, F.; Jiskoot, W.
    In:Vaccine, 28, 6282 - 6291. ISSN 0264-410x.

    Abstract:

    Nasal vaccination is a promising, needle-free alternative to classical vaccination. Nanoparticulate delivery systems have been reported to overcome the poor immunogenicity of nasally administered soluble antigens, but the characteristics of the ideal particle are unknown. This study correlates diffe

  • Conformation and intermolecular interactions of SA2 peptides self-assembled into vesicles (2010)Open access

    Authors:Hell, A.J. van; Klymchenko, A.; Burgers, P.P.M.; Moret, E.E.; Jiskoot, W.; Hennink, W.E.; Crommelin, D.J.A.; Mastrobattista, E.
    In:Journal of Physical Chemistry B, 114, 11046 - 11052. ISSN 1520-6106.

    Abstract:

    Previously we have shown that the recombinantly produced SA2 amphiphilic oligopeptide (Ac-Ala-Ala-Val-Val-Leu-Leu-Leu-Trp-Glu-Glu-COOH) self-assembles into nanovesicles (van Hell et al. 2007). In this study, the intermolecular interactions that contribute to the formation of such peptide vesicles ar

  • Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality (2009)

    Authors:Carpenter, J.F.; Randolph, T.W.; Jiskoot, W.; Crommelin, D.J.A.; Middaugh, C.R.; Winter, G.; Fan, Y.X.; Kirshner, S.; Verthelyi, D.; Kozlowski, S.; Clouse, K.A.; Swann, P.G.; Rosenberg, A.; Cherney, B.
    In:Journal of pharmaceutical sciences, 98, 1201 - 1205. ISSN 0022-3549.

    Abstract:

    Therapeutic protein products provide unique and effective treatments for numerous human diseases and medical conditions. In many cases, these treatments are used chronically to slow disease progression, reduce morbidity and/or to replace essential proteins that are not produced endogenously in patie

  • Preparation and characterization of protein loaded microspheres based on a hydroxylated aliphatic polyester, poly (lactic-co-hydroxymethyl glycolic acid) (2009)

    Authors:Ghassemi, A.H.; Steenbergen, M.J. van; Talsma, H.; Nostrum, C.F. van; Jiskoot, W.; Crommelin, D.J.A.; Hennink, W.E.
    In:Journal of Controlled Release, 138, 57 - 63. ISSN 0168-3659.

    Abstract:

    The purpose of this study was to investigate the suitability of a novel hydroxylated aliphatic polyester, poly (lactic-co-hydroxymethyl glycolic acid) (PLHMGA), as controlled release system for pharmaceutical proteins. Dextran Blue (as a macromolecular model compound) and lysozyme-loaded PLHMGA and

  • Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine (2009)

    Authors:Hagenaars, N.; Verheul, R.J.; Mooren, I.; Jong, P.H.J.L.F de; Mastrobattista, E.; Glansbeek, H.L.; Heldens, J.G.; Bosch, H. van den; Hennink, W.E.; Jiskoot, W.
    In:Journal of controlled release, 140, 126 - 33. ISSN 0168-3659.

    Abstract:

    The aim of this study was to assess the influence of structural properties of N,N,N-trimethyl chitosan (TMC) on its adjuvanticity. Therefore, TMCs with varying degrees of quaternization (DQ, 22-86%), O-methylation (DOM, 0-76%) and acetylation (DAc 9-54%) were formulated with whole inactivated influe

Pages:

previous
 < 1 2 3 4 > 

Go to page top
Go back to contents
Go back to site navigation